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Background: Exosomes, endosome-derived membrane microvesicles, contain specific RNA transcripts that are
thought to be involved in cell-cell communication. These RNA transcripts have great potential as disease
biomarkers. To characterize exosomal RNA profiles systemically, we performed RNA sequencing analysis using three
human plasma samples and evaluated the efficacies of small RNA library preparation protocols from three
manufacturers. In all we evaluated 14 libraries (7 replicates).
Results: From the 14 size-selected sequencing libraries, we obtained a total of 101.8 million raw single-end reads,
an average of about 7.27 million reads per library. Sequence analysis showed that there was a diverse collection of
the exosomal RNA species among which microRNAs (miRNAs) were the most abundant, making up over 42.32% of
all raw reads and 76.20% of all mappable reads. At the current read depth, 593 miRNAs were detectable. The five
most common miRNAs (miR-99a-5p, miR-128, miR-124-3p, miR-22-3p, and miR-99b-5p) collectively accounted for
48.99% of all mappable miRNA sequences. MiRNA target gene enrichment analysis suggested that the highly
abundant miRNAs may play an important role in biological functions such as protein phosphorylation, RNA splicing,
chromosomal abnormality, and angiogenesis. From the unknown RNA sequences, we predicted 185 potential
miRNA candidates. Furthermore, we detected significant fractions of other RNA species including ribosomal RNA
(9.16% of all mappable counts), long non-coding RNA (3.36%), piwi-interacting RNA (1.31%), transfer RNA (1.24%),
small nuclear RNA (0.18%), and small nucleolar RNA (0.01%); fragments of coding sequence (1.36%), 50 untranslated
region (0.21%), and 30 untranslated region (0.54%) were also present. In addition to the RNA composition of the
libraries, we found that the three tested commercial kits generated a sufficient number of DNA fragments for
sequencing but each had significant bias toward capturing specific RNAs.
Conclusions: This study demonstrated that a wide variety of RNA species are embedded in the circulating vesicles.
To our knowledge, this is the first report that applied deep sequencing to discover and characterize profiles of
plasma-derived exosomal RNAs. Further characterization of these extracellular RNAs in diverse human populations
will provide reference profiles and open new doors for the development of blood-based biomarkers for human
diseases.
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Many cells produce exosomes [1-3], small (30–100 nm)
membrane vesicles that are released into the extracellu-
lar environment by fusing with the plasma membrane
[4]. Although previously considered to be cellular waste
products, emerging evidence indicates that exosomes
can mediate diverse biological functions including angio-
genesis, cell proliferation, tumor cell invasion and me-
tastasis, immune response, and antigen presentation by
the transfer of proteins, mRNAs and non-coding RNAs
to neighboring or distant cells [3,5].
The existence of exosomes has been known for many
years; however, it is only recently that these lipid-rich
vesicles have been reported to contain an abundance of
nucleic acids, in particular small non-coding RNAs [6].
Studies have now shown that the packaging of RNAs
into exosomes is selective because the RNA profiles in
exosomes do not fully reflect the RNA profiles observed
in the parental cells [6-10]. When released from their
cells of origin, exosomes may enter blood or other bodily
fluids. To date, the microvesicles have been detected
in blood (plasma and serum), bronchoalveolar lavage,
urine, bile, ascites, breast milk, and cerebrospinal fluid
[8,11-26]. These circulating vesicles can be taken up
by recipient cells, allowing for cell-cell communication
regardless of the distance between the cells. Exosome-
mediated RNA transfer is believed to be an effective
method for cell signaling and the exosomal RNA will
certainly impact biological processes in the recipient
cells [8,27-29].
Exosomal RNAs have been implicated in many exosome-
mediated biological functions [30]. For example, RNAs
delivered by exosomes prepared from X-ray treated cells
were implicated in disseminating a bystander effect to tar-
get cells [31]. MicroRNAs (miRNAs) transferred by tumor-
derived exosomes were reported to down-regulate the
TAK1 pathway in hepatocarcinogenesis [32] and were piv-
otal in promoting tumor metastasis via a proinflammatory
cytokine-driven expansion of myeloid-derived suppressor
cells [33]. The let-7 miRNA family was selectively packaged
into exosomes from a metastatic gastric cancer cell line and
may have a role in the delivery of oncogenic signals to pro-
mote metastasis [34]. Exosomes derived from human
(HMC-1) and mouse (MC/9) mast cell lines transported
RNA to neighboring mast cells, impacting the function of
the recipient mast cells [6,35]. The miRNAs transferred by
the immune synapse were found to alter gene expression in
the recipient antigen presenting cells [8]. These findings
support the existence of a novel exosome-mediated mech-
anism by which one cell can regulate the activity or differ-
entiation of other cells.
While exosomes have been shown to play functional
roles in recipient cells, the RNA content of the exosomes
may provide unique molecular signatures for diseasediagnosis and prognosis [9,36-39]. It has been reported that
exosomes from diseased individuals contained RNAs that
were not found in healthy subjects [7,9]. These exosomes
may carry RNA signatures that are characteristic of the
parental cells, for example, tumor cells. So far, tumor-
derived exosomes have been identified in the plasma of pa-
tients with lung adenocarcinoma, glioblastoma multiforme,
malignant glioma, prostate cancer, and ovarian carcinoma
ascites [9,10,30,40,41]. The association of exosomal miR-
141 and miR-375 with metastatic prostate cancer has been
confirmed in a cohort of patients with recurrent or non-
recurrent cancer following radical prostatectomy [42].
These results suggest that circulating exosomes may pro-
vide a powerful tool for the non-invasive diagnosis and
prognosis of human diseases.
Most of the current studies have used microarray or
real time quantitative PCR (qPCR) assays to examine
exosomal RNAs, with a focus on miRNAs. Because of
the inherent limitations of these technologies, unknown
miRNAs or other RNA species are often undetectable.
Importantly, no systemic analysis of exosomal RNAs in
peripheral blood has been reported until now. Blood is
an important medium that allows exosomes to circulate
and deliver cell signaling molecules to any part of the
body. In this study, we performed a sequencing-based
RNA profiling analysis using the blood from three blood
donors. We evaluated three small RNA library prepar-
ation protocols and systemically characterized the extra-
cellular RNA species. This study will provide a general
guideline for blood-based exosomal RNA sequencing
analysis and contribute to an understanding of exosome-
mediated biological functions and mechanisms.
Results
Exosome size and RNA stability
We used the NanoSight LM10 instrument to determine
the size distribution and concentration of the exosomes.
For the three samples tested, the exosome sizes ranged
from 30–90 nm (Figure 1A). The number of exosomes
per 250 μL of plasma ranged from 0.21–1.08 × 108 and
the RNA yields from each of the samples were similar,
ranging from 10–15 ng (as determined using an Agilent
Bioanalyzer). The RNAs sizes ranged from 18–28 nucle-
otides (nt) (Figure 1B). We repeated the RNA extraction
at least twice for each sample. The RNA size distribu-
tions and yields were consistent both between extrac-
tions and between samples. We also ran an Agilent RNA
6000 Pico chip and found no evidence of cellular RNA
contamination (Figure 1C). In subsequent enzyme pro-
tection assays, we treated the isolated nucleic acids with
DNase I and found that there was no significant degrad-
ation; however, when treated with RNase A, the isolated
nucleic acids were completely degraded (Figure 1D). To
test whether or not the exosome membrane protected
Figure 1 Exosome isolation and exosomal small RNA quantification. (A) Representative histogram of exosome size distribution. (B) Exosomal
RNAs determined using the Agilent Small RNA Chip. The small RNAs were dominant in the exosomal RNAs. (C) Exosomal RNAs determined by
the Agilent RNA Pico Chip. Exosomal RNA samples A, B and C contained no detectable 18S and 28S rRNAs. Cellular RNA from HEK293 was
loaded as positive control for 18S and 28S rRNAs (D) Isolated exosomal RNAs treated either with DNase I or RNase A. (E) Plasma and control small
RNAs treated under various conditions.
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ples with RNase A under various conditions and obtained
high yield of RNAs in the samples after the treatment
(Figure 1E).
Comparison of three small RNA library preparation
protocols
To compare three commercially available library prep-
aration kits, we constructed sequencing libraries using
2 ng of exosomal RNA and 15 PCR cycles for all the
preparations. We found that there were significant differ-
ences in the size distribution of the amplified libraries
when comparing the three different preparation proto-
cols. Each of the protocols was expected to have sequen-
cing library size of 140–160 bp. Among these kits, the
NEBNext multiplex small RNA library preparation kit
(NEB) produced more target fragments that were sepa-
rated from adaptor dimers (Figure 2A). The Illumina kit
constantly generated a strong DNA fragment of ~180 bp,
but the target fragments were hardly seen. The Bioo Sci-
entific kit generated fragments of the expected size, but
separation with adaptor dimers was poor. Although all
three kits generated enough DNA at the targeted size for
sequencing, the pre-sequencing qPCR results showed
that the NEB kit produced the highest yield of recovered
RNA-seq libraries with less variation.
Data processing and genome mapping
We replicated each of the three samples and tested each
replicate in at least two separate library preparationprotocols. In all we produced a total of 14 sequencing
libraries (7 replicates). From the 14 libraries, we
obtained a total of 101,804,712 raw single-end reads, an
average of about 7.27 million reads per library. Among
the raw reads, we found 73,112,422 (71.82%) sequences
with insert lengths ≥16nt (query sequences) and of
these, 55.54% (56,542,143) could be mapped to known
RNAs and to the human genome (Table 1). In 12 of the
14 libraries, at least 50% of the raw reads were map-
pable sequences (Figure 2B). On average, the NEB li-
braries had the highest percentage of mappable reads
(62.72%) while the Bioo Scientific and Illimina libraries
had 50.07% and 51.15% mappable reads, respectively.
The size distribution of the inserts also varied among
these kits. The NEB libraries had the highest propor-
tion of 21–23 nt inserts, followed by Illumina and Bioo
Scientific kit [see Additional file 1]. Nevertheless, in all
three libraries, miRNA sequences were the most com-
mon, accounting for 76.20% of the mappable reads
(Table 1).
Exosomal miRNA content
Because the abundance of most miRNAs is low in the
exosomes, we defined detectable miRNAs as those
that had at least one sequence per million mappable
miRNA reads. Accordingly, we detected a total of 593
known miRNAs in the 14 libraries. In each individual
library, the number of detectable known miRNAs var-
ied from 380 to 474 with an average of 419 [see Additional
file 2]. To validate the sequencing data, we selected three
Figure 2 Library preparation and analysis of the raw sequencing data. (A) PAGE analysis of the sequencing libraries prepared using three
different kits. 20-bp DNA ladders are shown on the left of each panel while the prepared libraries are shown on the right. The anticipated RNA
sequencing constructs ranging from 140–160 bp are highlighted within brackets. The DNA bands (~125 bp) are the adaptor dimers. (B) Percentage
of mappable RNAs in the raw sequencing reads. (C) Abundance of the selected miRNAs and β-actin in plasma exosomal RNA and HEK293 cellular
RNA. Gene and miRNA abundance was determined by the threshold cycle (Ct), where Ct values >30 are defined as rare. (D) Percentage of each
miRNA in the repertoire of total miRNA reads.
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cation; namely, miR-92a-3p, which had a high read
count, and miR-191-3p and miR-26b-5p, which had
relatively low counts. HEK293 cellular RNA was used
as a positive control. The results showed that the ex-
pression levels of miR-92a-3p and miR-191-3p were
385 and 4.6 fold higher than the expression level of
miR-26b-5p (Figure 2C). These relative abundance ra-
tios were close to the ratios from the sequencing data
using the Illumina kit (441 fold for miR-92a-3p versus
miR-26b-5p, and 10.7 fold for miR-191-3p versus
miR-26b-5p). As anticipated, the expression level of
β-actin was extremely high in cells, but hardly de-
tectable in the exosomes. The five most abundant
miRNAs in the libraries were miR-99a-5p, miR-128,
miR-124-3p, miR-22-3p, and miR-99b-5p, which to-
gether accounted for 48.99% of all detectable miRNAs
(Table 2). The 100 most abundant miRNAs made up
97.47% of the detectable miRNA sequences; therefore,
the remaining 493 low abundant miRNAs accounted
for only 2.53% (Figure 2D).Variability of miRNAs between technical replicates,
samples, and preparation protocols
To examine the variations of the miRNA contents that
may be produced by potential technical and biological
variability, we performed a correlation coefficient ana-
lysis using log2 transformed values after normalizing
reads to per million counts. For the seven pairs of tech-
nical replicates, the overall reproducibility was excellent
regardless of the kits used (average Pearson correlation
coefficient r = 0.98) (Figure 3A). The highest correlations
were observed between the NEB replicates (r = 0.994),
followed by the Bioo Scientific (r = 0.984) and Illumina
(r = 0.978) replicates.
For sample-sample (biological) variations, we com-
pared pooled samples (samples A, B and C) prepared
using the Bioo Scientific and NEB kits. Overall, we found
that there was significant correlation between samples B
and C (r = 0.986) (Figure 3B), followed by between sam-
ples A and B (r = 0.983), and then between samples A
and C (r = 0.981). However, when comparing the varia-
tions among the different library preparation protocols,
Table 2 The twenty most abundant miRNAs among the plasma exosomal RNAs (normalized read counts per million
mappable miRNAs)
miRNA ILMN Bioo Scientific NEB
A1 A2 A1 A2 B1 B2 C1 C2 A1 A2 B1 B2 C1 C2
hsa-miR-99a-5p 17604 16094 211064 186965 259315 347052 185255 186911 123880 127903 178157 181267 148618 156684
hsa-miR-128 23296 24353 13735 5650 1634 8538 3164 3488 240820 246854 196217 198956 271367 289239
hsa-miR-124-3p 3965 4924 172880 202866 272353 142389 294247 227036 7409 6878 8012 8298 5548 5935
hsa-miR-22-3p 88942 90113 104977 114037 89815 74092 103413 105707 22263 23545 30113 31787 25136 27245
hsa-miR-99b-5p 147955 140925 19482 22631 70340 51141 30682 28513 12113 12021 16975 16029 14154 12804
hsa-miR-181a-5p 71811 74929 30810 27391 16161 18060 19530 22364 18741 20040 24994 25733 19369 21147
hsa-miR-9-3p 2452 2261 47411 45386 15754 21748 37897 51888 25442 24983 34070 34203 26904 26030
hsa-miR-100-5p 29843 26438 34978 13511 15176 71812 11906 13708 20410 20201 23359 22036 21868 19371
hsa-miR-129-5p 1239 1250 1499 2226 2018 1263 3468 3002 36690 38005 65007 65498 44690 43875
hsa-miR-125b-5p 16643 14233 41087 38871 28081 37343 13492 16907 18291 17186 13985 13735 16600 14989
hsa-miR-9-5p 1660 1722 4935 6023 3524 3777 9878 10890 55445 49993 33259 32108 35887 30142
hsa-miR-27b-3p 42215 44272 14583 18653 8155 8121 10445 12335 18378 18108 14894 14884 16922 16602
hsa-miR-486-5p 103037 110538 4378 3697 565 1518 1087 1538 2605 2452 575 559 704 675
hsa-miR-181b-5p 12367 12732 11171 10640 6771 8423 9149 11734 17762 18681 23870 24021 19829 20536
hsa-miR-125a-5p 64362 48420 11387 13447 7045 9135 5385 6101 10799 9895 2968 2867 8081 6412
hsa-miR-127-3p 29214 32718 14617 13023 15528 20062 7562 9800 7162 7135 7944 7654 7082 6660
hsa-miR-92b-3p 56679 56085 6098 8510 13143 7791 10936 9280 2522 2413 3184 3311 3030 2921
hsa-let-7i-5p 4741 5176 6153 6734 3550 3128 5004 5179 34309 31210 19278 18343 18410 15844
hsa-miR-320a 1525 1553 6928 6594 7967 10042 6811 9426 14608 14321 26781 25923 17449 14913
hsa-let-7b-5p 1354 1395 4754 4563 3452 4111 1845 2568 21801 25102 22716 22410 21734 23257
Table 1 Sequence read counts from RNA sequencing for the 14 libraries
Kit Samples Raw reads Query reads Mappable reads
miRNAs (%) Others (%)
Illumina
A1 5,038,311 3,629,688 2,003,390(76.7) 607,629(23.3)
A2 5,643,622 3,753,814 2,030,007(71.3) 819,077(28.7)
Bioo Scientific
A1 6,506,144 4,850,351 3,395,109(85.3) 587,039(14.7)
A2 8,143,961 5,632,208 3,998,520(84.4) 741,200(15.6)
B1 7,586,416 5,129,990 2,847,137(75.4) 927,909(24.6)
B2 6,365,053 5,246,494 3,111,194(77.8) 885,208(22.2)
C1 9,039,025 2,446,141 1,490,184(75.3) 487,517(24.7)
C2 5,622,703 3,270,113 2,006,209(76.6) 612,942(23.4)
NEB
A1 7,990,894 6,575,021 4,419,868(81.5) 1,004,342(18.5)
A2 8,038,976 6,605,662 4,507,678(81.8) 1,000,301(18.2)
B1 7,257,368 6,342,279 2,653,105(61.2) 1,684,951(38.8)
B2 8,268,147 7,302,007 3,107,916(62.1) 1,898,996(37.9)
C1 9,429,406 7,138,699 4,219,991(76.5) 1,298,809(23.5)
C2 6,874,686 5,189,955 3,294,935(78.5) 900,978(21.5)
Total 101,804,712 73,112,422 43,085,243(76.2) 13,456,898(23.8)
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Figure 3 miRNA correlations between technical replication, biological replication and methodological replication. (A) Scatter plots of
technical replicates in sample A. Illumina kit (ILMN), left panel (r = 0.978); Bioo Scientific kit (BS), middle panel (r = 0.984); and NEB kit, right
panel (r = 0.994). (B) Scatter plots of sample A and sample B (left panel, r = 0.983); sample B and C (middle panel, r = 0.986), and sample A and
C (right panel, r = 0.981). Only the plots for the pooled samples are shown. (C) Scatter plots of ILMN and BS (left panel, r = 0.889), ILMN and
NEB (middle panel, r = 0.866), and BS and NEB (right panel, r = 0.898). Only the plots for the pooled samples are shown. (D) Heat map of
unsupervised hierarchical clustering of the 100 most abundant miRNAs. Samples and library preparation methods are indicated on horizontal
axis at the top of the heat map. miRNAs are indicated vertically on the right.
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ation coefficient r value was close to 0.884. The correlation
r values were 0.898 between NEB and Bioo Scientific
(Figure 3C), 0.889 between Bioo Scientific and Illumima,
and 0.866 between NEB and Illumima.
To better demonstrate the technical, biological, and
methodological variations, we performed an unsuper-
vised hierarchical clustering analysis using the log2-
transformed sequence counts of the 100 most abundant
miRNA transcripts. As expected, the heat map showed
that there was a clear separation between groups com-
posed of replicates, samples and library preparation kits
(Figure 3D). Nearly all of the 100 miRNAs showed similar
expression patterns between technical replicates; however,
some of them showed significant variations among differ-
ent samples and most showed differences among different
preparation kits. For example, the NEB kit detected over
21 fold more miR-129-5p sequences than either the
Illumina or the Bioo Scientific kits. The Illumina kit gener-
ated over 50 fold more miR-486-5p sequences in sample A
than either the Bioo Scientific or the NEB kits. The Bioo
Scientific kit produced over 31 fold more miR-124-3p se-
quences than either the Illumina or the NEB kits. The
methodological variations were also evident for the top 20
most abundant miRNAs (Table 2).
Sharing of detectable miRNAs
To examine if the miRNAs were unique to or common
to the different preparation protocols, we first removed
the low abundant miRNAs (<5 normalized counts per
million miRNA reads) and then compared the remaining
miRNAs among the three kits. Sample A was used for
the comparison because this was the only sample that
was tested in all three kits. The Illumina, Bioo Scientific
and NEB kits detected 317, 364 and 370 known
miRNAs, respectively. Of these, 287 were detected by all
three kits (Figure 4A). In addition to the miRNAs thatFigure 4 Venn diagrams showing miRNAs that are common in
the three samples. (A) Unique and shared miRNAs in sample A in
the libraries prepared using the different kits. (B) Unique and shared
miRNAs in the different samples. The miRNAs with read counts ≥5
per million mappable sequences were used for the comparison.were shared, we also identified some miRNAs that were
unique to one particular library preparation protocol. For
example, miR-2964-3p and miR-3065-5p were detected
only by the Bioo Scientific kit. However, the abundance
of the unique miRNAs were generally low in the libraries
[see Additional file 2].
Additionally, we examined different samples for miRNA
that were shared. Samples A, B and C each had 379, 343
and 356 miRNAs with >5 reads per million, respectively
and 328 of them were shared among the three samples.
Samples A, B and C also had 29, 3, and 10 unique
miRNAs, respectively (Figure 4B). However, similar to the
findings for the methodological differences, most of the
sample-specific miRNAs were low in abundance.
Other RNA species
To annotate the exosomal RNA species that were not
identified as miRNA transcripts, we first removed all the
known miRNA sequences from the libraries and then
mapped the remaining sequences to the human genome
that had RNA annotations. Figure 5A shows the percent-
age of other small non-coding RNAs, tRNA, rRNA,
small nuclear (snRNA), small nucleolar (snoRNA) and
piwi-interacting RNA (piRNA) that were detected. The
rRNA was the most common among them, accounting
for 9.16% of all mappable counts, followed by piRNA
(1.31%), tRNA (1.24%), snRNA (0.18%), and snoRNA
(0.01%). Clearly, the exosomes contained relatively low
levels of rRNA, which is in contrast to a typical
eukaryotic cell where rRNA makes up at least 80% of
the total RNA molecules. Interestingly, we also detected
low levels of “long” RNA in the small RNA libraries. We
detected 3.36% of long non-coding RNA (lncRNA),
1.36% of coding sequences (CDS), 0.54% of 3′untrans-
lated region (UTR) and 0.21% of 5′UTR sequences [see
Additional file 3]. Compared to cellular RNA compo-
nents, the CDSs in the exosomal RNAs accounted for a
much smaller fraction of all mappable sequences. In
addition, we found 0.21% of other RNA sequences that
mapped to species other than human. For instance, the
bovine bta-miR-6529 was the most common non-human
miRNA found in the 14 libraries. However, this result
should be interpreted with caution because most, if not
all, of “non-human” RNAs may be an artifact [43].
The most abundant of the gene fragments that
contained the CDS, 5′UTR or 3′UTR sequences that
were found in the small RNA libraries were involved
in fundamental metabolic processes [see Additional
file 3]. For example, the most common CDS se-
quences mapped to NYNRIN [GenBank:NM_025081]
and LARS2 [GenBank:NM_015340], both of which en-
code proteins that participate in tRNA or rRNA me-
tabolism. The most frequent 5′UTR sequence mapped
to PVRL2 [GenBank:NM_001042724], which encodes
Figure 5 Other RNA species that were detected in the exosomal RNA libraries. (A) Pie chart of RNA species and their distributions in the
plasma-derived exosomes. Misc RNAs are the RNA sequences that mapped to the human genome but not in any of the categories listed. The
DNA category represents the novel transcripts that have no annotation in the human RNA database. (B) Graphic and statistics of a representative
novel miRNA predicted by miRDeep2. Both star and mature strands were detected and integrated. Lower left table shows information about the
sample and the miRDeep2 scores, along with the read count for each component of the putative miRNA. mm, number of mismatches.
Mismatched nucleotides are indicated by uppercase letters.
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herpes simplex virus and pseudorabies viruses [44].
The second most common 5′UTR sequence mapped to
ENTPD4 [GenBank: NM_004901], which encodes an
endo-apyrase that is capable of cleaving nucleoside tri-
and/or di-phosphates [45]. The most frequent 3′UTR
sequence mapped to PAQR5 [GenBank:NM_017705],
which encodes progestin and adipoQ receptor family
member V, which functions as a membrane progester-
one receptor [46].Predicted novel miRNAs
To identify novel miRNAs in the 14 libraries, all the raw
data were processed independently using miRDeep2 [47].
The miRDeep2 software detected 185 distinct novel
miRNAs in the 14 libraries and 15, 88 and 111 novel
miRNAs in the individual libraries generated by the
Illumina, Bioo Scientific and NEB kits, respectively [see
Additional file 4]. Among the putative miRNAs, two were
common to libraries prepared with the Illumina and NEB
kits, six were common to the Illumina and Bioo Scientific
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tific libraries. Of the 15 putative miRNAs in the Illumina li-
braries, four (26.7%) were found in technical replicates. For
the Bioo Scientific-derived library, 16 of the 88 novel
miRNAs (18.2%) were found in at least two replications
and 19 (21.6%) were common to at least two samples. For
the NEB-derived libraries, 33 of the 111 novel miRNAs
(29.7%) were present in technical replicates and 38 (34.2%)
were common to at least two samples. A representative
readout of the predicted miRNAs from an NEB library is
shown in Figure 5B. Multiple reads of both the mature and
star miRNA sequences (typical components of a miRNA)
were found in this library. All of the predicted miRNAs
had the typical miRNA features at genomic DNA level.
Potential regulatory roles of exosomal miRNAs
We performed gene enrichment analysis using a set of
genes that were predicted to be targets of the highly
abundant miRNAs in the exosomes. The miRDA tool
(http://mirdb.org/) predicted a total of 1205 target genes
for the top five exosomal miRNAs. We found significant
enrichment of these genes in gene ontology (GO)
terms, including protein phosphorylation, RNA spli-
cing, chromosomal abnormality, and angiogenesis. For
example, we found a 1.33 fold enrichment of phospho-
proteins (Bonferroni p = 1.35E-17), a 1.23 fold enrichment
of splice variants (Bonferroni p = 3.43E-7), and a 2.46 fold
enrichment of genes involving chromosomal rearrange-
ment (Bonferroni p = 5.81E-5) (Table 3). Interestingly, we
also observed significant enrichment in vasculature devel-
opment (2.22 fold enrichment, Bonferroni p = 3.75E-2) and
neurotrophin signaling pathway (2.68 fold enrichment,
Boferroni p = 8.07E-3).
Discussion
Exosomes circulating in the blood carry regulatory RNA





phosphoprotein 1.33 2.51E-20 1.35E-17
splice variant 1.23 1.20E-10 3.43E-07




mutagenesis site 1.40 1.51E-06 4.31E-03
kinase 1.76 1.82E-06 9.83E-04
cytoplasm 1.27 9.43E-06 5.08E-03
vasculature development 2.22 1.26E-05 3.75E-02
neurotrophin signaling pathway 2.68 4.94E-05 8.07E-03
endosome 2.01 5.44E-05 2.44E-02communication. Because diseased cells, including tumor
cells, actively release exosomes into the blood stream,
the circulating exosomes may provide a stable source of
RNAs for disease diagnosis, prognosis and treatment
management [2,6,39,48]. In this study, we developed a
protocol for isolating exosomal small RNA from a very
low volume of plasma. We performed deep sequencing
analysis of the exosomal RNAs, and generated expres-
sion profiles of the important extracellular RNAs. Our
findings will not only help characterize the RNA content
of exosomes but will also contribute to understanding
exosome function and biology.
Exosomal RNA profiling analysis is not possible without
high quality RNA. Compared to cellular RNAs, exosomal
RNAs are more stable [49], and are reportedly resistant to
physical degradation such as prolonged storage and freeze/
thaw cycles [50]. The circulating exosomal RNAs have
been found to be resistant to biochemical degradation by
ribonuclease in serum as well as by RNase A under an
in vitro condition. This stability makes reproducible and
consistent evaluation of blood-based non-coding RNA
possible [51]. Indeed, our study strongly supports the
protective role of the microvesicles or other proteins
in the stability of the circulating plasma RNA. Recently,
Argonaute 2 was reported to bind and protect miRNAs
from degradation in the circulation [52]. It appears that
Argonaute 2-protected miRNAs contribute to a signifi-
cant proportion of the RNA circulating in the blood.
Therefore, RNAs (at least miRNAs) in the blood stream
are protected by multiple mechanisms and may be
more stable than previously believed [53].
The dominant size of the exosomal RNA that was
detected in this study was 18–28 nt. This size range is
apparently smaller than that of the small RNAs derived
from culture medium [34,54,55], where the sizes were
centered at about 70 nt. Different isolation methods may
account for the size discrepancies. Ultracentrifugation at
100,000 g seems to be less capable of discriminating
exosomes from other microvesicles, especially when the
exosomes are large. The mixed sizes of the isolated
microvesicles may have caused more heterogeneity of
RNA biotypes, which in turn impacted on the size and
abundance of the RNAs in the libraries. In addition, the
ExoQuick-based assay that we used to precipitate the
exosomes may co-precipitate non-exosomal microparti-
cles or RNA-binding proteins. Therefore, technically, the
exosomal RNA may account for a fraction of all RNAs
isolated by this assay. To obtain reproducible and reli-
able expression data, further study of the isolation
methods is highly recommended.
The highly enriched exosomal miRNAs may have sig-
nificant impacts on the target cells. For example, miR-
99a-5p, the most abundant miRNA in the plasma
exosomes, functions in a tissue-dependent manner. In
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down-regulated and its overexpression in a prostate can-
cer cell line was reported to inhibit the growth of the re-
cipient cells and decreased the expression of the
prostate-specific antigen [56]. However, overexpression
of the miR-99a was also reported to be responsible for
increased proliferation, migration and fibronectin levels
in a murine epithelial cell line NMUMG, possibly via
modulating the TGF-β pathway [57]. The functional role
of miR-124 as a tumor suppressor has been established
in glioblastoma, breast cancer, hepatocellular carcinoma,
gastric cancer, and prostate cancer [58-62]. Another
study demonstrated that miR-124 silencing in neuro-
blastoma cells led to cell differentiation, cell cycle arrest
and apoptosis [63]. In support of the important func-
tions of the highly expressed exosomal miRNAs, our
GO-based target prediction showed their potential roles
in phosphorylation, RNA splicing, chromosomal abnor-
mality, and angiogenesis; however, these predictions
need further functional confirmation. Clearly, once re-
leased into target cells, the highly enriched miRNAs may
participate directly in the regulation of mRNA transla-
tion and influence cell functions.
We also observed low level of “long” RNA fragments
such as mRNA and lncRNA in the small RNA sequencing
libraries. Our library preparation protocols were designed
to capture small non-coding RNAs (~20–40 nt long).
Therefore, the mRNAs and lncRNAs that were identified
in this study should all be treated as fragmented RNAs.
The procedures that were used for RNA extraction and li-
brary preparation may have caused partial RNA degrad-
ation, enabling the detection of fragments of the long
RNAs in the small RNA libraries. Another possible explan-
ation for the presence of long RNA fragments is that the
exosomes also function as a “reservoir” to remove de-
graded mRNA and lncRNA derived from the cytosol. The
exact mechanism underlying the presence of fragmented
long RNAs in exosomes remains to be unraveled.
The current study demonstrated the reproducibility for
each library preparation kit. Both Pearson correlation
and hierarchical cluster analysis showed highly correlated
RNA profiles between technical replicates, suggesting the
consistency of these commercial kits. However, the study
also showed significant biases between the library prepar-
ation methods. Each kit preferentially captured specific
RNA sequences. For high abundant RNAs, this bias does
not seem to be problematic because all three kits
detected these RNAs. For low abundant RNAs, however,
the bias could be an issue because these RNAs may be
detected by one kit but not by another. Protocol-based
bias may also create problems in data interpretation if
different commercial kits are used. We suggest that sep-
arate validation using qPCR should be performed for all
sequencing-based detections.The ever growing number of novel sequences in the
miRNA database implies that human miRNA annotation
is far from complete [64]. To identify novel miRNAs,
next generation sequencing is the most powerful and the
most popular approach. However, systematic bias during
library preparation and the limited power of prediction
algorithms means that some of the novel miRNAs may
have been falsely predicted. We strongly recommended
using other complementary methods such as Northern
blot and qPCR for subsequent validation. Additionally,
this study used only three plasma samples and, there-
fore, our findings may not fully represent all exosomal
RNAs in human populations. To completely survey the
exosomal transcriptome more samples from diverse pop-
ulations and with different disease status are required.
The plasma exosomes are believed to be derived from
a variety of cell populations. Their heterogeneous origin
may limit the detection of disease-specific exosomes in
peripheral blood samples. Vast numbers of exosomes
shed from other cell types may dilute the exosome popu-
lation derived from tumor cells, significantly reducing
the proportion of tumor-derived miRNAs in the sequen-
cing libraries. Because the less common tumor-derived
miRNA may be a direct reflection of the disease status
and critical for tumor development, the increased read
depth of RNA sequencing is required. It is worth men-
tioning, that although the detection of rare RNA tran-
scripts will increase as sequencing depth increases, the
rare sequences still account for a tiny fraction of the
exosomal RNAs. Whether or not the rare exosomal
miRNAs are functional remains to be determined.
Conclusions
We developed a comprehensive data-generation and data-
analysis pipeline that includes exosome isolation, RNA ex-
traction, library preparation, RNA sequencing, and RNA
annotation. Our data show that plasma-derived exosomes
contain diverse RNA species, in particular, miRNA. The
abundance of the exosomal RNAs varies dramatically.
Some highly abundant miRNAs may play critical roles after
being transferred to target cells. The three commercial
small RNA preparation kits that we tested generated suffi-
cient DNA fragments for sequencing but had significant
biases towards capturing specific RNAs. The use of large-
scale RNA sequencing will ensure the discovery and
characterization of the whole transcriptome (known and
unknown RNAs) of the blood-derived exosomes, which
has not been completely examined so far. A fully character-
ized transcriptome will help gain a better understanding of
exosome-mediated molecular mechanisms and will con-
tribute to biomarker discovery. It is expected that the
blood-based sequencing assay described here will find clin-
ical applications as a biomarker discovery tool for disease
diagnosis and prognosis.
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Study design and participant consent
The objective of this study was to provide general guide-
lines for profiling analysis of exosomal RNA in peripheral
blood. To accomplish this goal, we selected plasma sam-
ples (samples A, B and C) from three anonymous blood
donors and split each sample into two for technical repli-
cation. We tested the six samples (A1 and A2, B1 and
B2, C1 and C2) using two small RNA library preparation
kits: NEBNext multiplex small RNA library preparation
kit (NEB, New England Biolab, Ipswich, MA, USA) and
NEXTflex small RNA sequencing kit (Bioo Scientific,
Austin, TX, USA). We also tested samples A1 and A2
using the TruSeq small RNA sample preparation kit
(Illumina, San Diego, CA, USA). Altogether, we tested
the six plasma samples by sequencing the 14 indexed li-
braries prepared using the three kits as described above.
This study allowed the direct comparison of three cur-
rently available small RNA library preparation protocols
and identified the most suitable strategy for future
exosomal RNA sequencing analysis. A flowchart of the
study design is shown in Figure 6. The participants gave
written informed consent for their blood to be used for
this study. The use of the human biospecimens was ap-
proved by the Institutional Review Board of the Medical
College of Wisconsin and the Mayo Clinic.
Exosome isolation
Human plasma samples were obtained from the Mayo
Clinic and stored at −80°C before use. Exosomes were
isolated from 250 μL of plasma using the ExoQuick
exosome precipitation solution (System Biosciences,
Mountain View, CA, USA) according to the manufac-
turer’s instructions with minor modifications. Briefly, the
plasma was incubated with thromboplastin D (Thermo
Scientific, Middletown, VA, USA) for 15 min at 37°C.
After centrifugation at 10,000 rpm for 5 min, the super-
natant was mixed with 75 μL of ExoQuick solution and
RNase A (Sigma, St. Louis, MO, USA) to a final concen-
tration of 10 μg/mL. The mixture was kept at 4°C over-
night and then further mixed with 150 units/mL ofFigure 6 Schematic illustration of the study design. Three
plasma samples (A, B and C) were used in this study. Each sample
had a technical replicate. Three commercial kits were tested:
ILMN-Illumina, BS-Bioo Scientific and NEB-New England Biolab.murine RNase inhibitor (NEB) before centrifugation at
1500 g for 30 min. The exosome pellet was dissolved in
25 μL 1 × PBS; 2 μL of the solution was reserved for
evaluation of exosome size and concentration using the
NanoSight LM10 instrument (Particle Characterization
Laboratories, Novato, CA, USA), and RNA was extracted
immediately from the remaining solution.
Exosome quantitation and size determination
The concentration and size distribution of the isolated
exosomes were measured using NanoSight. Prior to
sampling, the sample solutions were homogenized by
vortexing, followed by serial dilution to a final dilution
of 1:100,000 in 0.2 μm-filtered 1x PBS. The National
Institute of Standards and Technology (NIST) traceable
97 nm ± 3 nm polystyrene latex standards were added
and analyzed along with the diluted exosome solution
to validate the operation of the instrumentation. A
blank 0.2 μm-filtered 1x PBS was also run as a nega-
tive control. Each sample analysis was conducted for
90 seconds. The Nanosight automatic analysis settings
(high sensitivity, blue laser [405 nm, 645 mW]) were
used to process the data. All samples were evaluated
in triplicate.
RNA isolation
Exosomal or HEK293 cellular RNA was prepared using
a miRNeasy Micro Kit (QIAGEN, Valencia, CA, USA).
Twenty-three μL of exosome suspension or 1 × 106
HEK293 cells were mixed with 700 μL QIAzol lysis buf-
fer, and the mixture was processed according to the
manufacturer’s standard protocol. The extracted RNA
was eluted with 14 μL of RNase-free water. The quantity
and quality of the RNA were determined by Agilent
Bioanalyzer 2100 with a Small RNA Chip for exosomal
RNA, and a RNA 6000 Pico Kit for cellular RNA (Agilent
Technologies, Santa Clara, CA, USA).
Enzyme protection assay
RNA isolated from the plasma exosomes was first incu-
bated at room temperature, either with 30 units/μL of
DNase I (QIAGEN) for 10 min or with 10 μg/mL
RNase A for 30 min. The RNase A digestion was termi-
nated by adding 150 units/mL of murine RNase inhibi-
tor. The resultant RNA samples were processed with
the Agilent Bioanalyzer. In another enzyme protection
assay, before the addition of murine RNase inhibitor,
plasma samples were incubated with 10 μg/mL RNase
A under various conditions, namely, at 37°C for 15 min,
at room temperature for 30 min, or at 4°C overnight,
followed by exosome isolation and RNA extraction. The
same procedure was carried out using commercially
available small RNA, which acted as a control for this
assay. The RNA eluents along with the naked small
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RNA library preparation
For each library, 2 ng of small RNA was used in all the
experimental procedures. Each library was prepared with
a unique indexed primer so that the libraries could all
be pooled into one sequencing lane. The 14 RNA librar-
ies were prepared and amplified following the instruc-
tion of each manufacturer. The amplified libraries were
resolved on a native 5% acrylamide gel. DNA fragments
from 140–160 bp (the length of miRNA inserts plus the
3′ and 5′ adaptors) were recovered in 12 μL elution buf-
fer (QIAGEN). The indexed libraries were quantified on
the Bio-Rad 1000 qPCR instrument using the KAPA
Library Quantification Kit in triplicates, according to
the manufacture’s protocol (Kapa Biosystems, Woburn,
MA, USA). Ten μL of the pooled library at a final con-
centration of 2 nM were then sent to the Core Facility at
Medical College of Wisconsin for sequencing using
Illumina HiSeq2000 DNA sequence analyzer.
Sequencing data analysis
Perl scripts (available upon request) were developed to
process the data from the RNA sequencing. Raw reads
were first extracted from FASTQ files, and trimmed
using a sequencing quality control of Q >13 [65]. Then
the 3′ adaptor sequences within the read sequences were
cleaned up. The prepared sequences were filtered and
sequences with lengths ≥16 nt were aligned using Bowtie
(version 0.12.8) [66] against both the human miRNA se-
quences downloaded from miRBase (Release 19, 2043
entries) [67] and the human genome reference sequences
downloaded from the NCBI ftp site (Release 103). The
Bowtie parameters that were used for the alignments
were: -m 3 -n 1 -f -a –best –strata. Normalization of the
miRNA profiles was based on the following formula:
(read counts of an individual miRNA/sum of read
counts of all mappable miRNAs) multiplied by 1 × 106.
The RNA sequencing data are available from the NCBI
Gene Expression Omnibus database [GEO: GSE45722].
Quantitative real-time PCR
To validate the RNA sequencing data, we performed a
qPCR analysis of miR-92a-3p, miR-191-3p, miR26b-5p,
and β-actin. The miRNA-specific miScript Primer As-
says and the primer set specific for β-actin were pur-
chased from QIAGEN (MS00006594 for miR-92a-3p,
MS00031528 for miR-191-3p, MS00003234 for miR26b-
5p, and QT01680476 for β-actin). First, 5 ng exosomal
RNA or 20 ng cellular RNA was reverse transcribed by
the miScript II RT kit (QIAGEN) at 37°C for 60 min,
and then the enzyme was inactivated at 95°C for 5 min.
After the activation of the polymerase enzyme at 95°Cfor 15 min, 40 cycles of 94°C for 15 s, 55°C for 30 s, and
72°C for 30 s were performed on the SteponePlus instru-
ment (ABI). Melting curve analysis was used to confirm
the specificity of the amplification reactions.
Prediction of novel miRNA
To find novel miRNAs, we applied miRDeep2 and
processed the raw sequencing data independently [47].
Predicted miRNAs with miRDeep2 total scores ≥2 were
considered to be significant. If a predicted miRNA se-
quence resembled a reference rRNA or tRNA sequence,
the sequence was discarded in the subsequent analysis
regardless of the score.
miRNA target gene enrichment analysis
We downloaded all miRNA target genes from miRDB
(http://mirdb.org/miRDB/), an online database for miRNA
target prediction and functional annotations. All the tar-
gets were predicted using MirTarget2 [68,69]. DAVID
was used for the significant gene enrichment analysis.
DAVID (Database for Annotation, Visualization and Inte-
grated Discovery) (http://david.abcc.ncifcrf.gov/) provides a
comprehensive set of functional annotation tools to under-
stand biological meaning behind large list of genes [70].
Because each miRNA could target hundreds of genes,
we limited the analysis to the top five most abundant
exosomal miRNAs.
Additional files
Additional file 1: Percentage of read counts with different insert
sizes among the total mappable reads. The NEBNext multiplex small
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the averages of the three different kits that were tested.
Additional file 2: Read counts of the miRNAs detected in the 14
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